ANACOR TO PRESENT AT COWEN AND COMPANY HEALTH CARE CONFERENCE

Palo Alto, CA—March 3, 2010—Anacor Pharmaceuticals announced today that David Perry, Chief Executive Officer, will provide a company overview at the Cowen and Company 30th Annual Health Care Conference at 4:00 p.m. ET on Tuesday, March 9, 2010 in Boston.

About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform. Anacor focused initially on developing topical applications of its compounds to treat fungal, bacterial and inflammatory diseases. In addition, the Company is developing systemic antibacterial therapeutics under a research and development agreement with GlaxoSmithKline. Anacor's most advanced product candidate is AN2690, a novel topical antifungal in development for the treatment of toenail onychomycosis, which is a fungal infection of the nail and nail bed. For more information visit www.anacor.com.

Contact:
Anne Bowdidge
Investor Relations
650-543-7575